Allurion Technologies (ALUR)
OTHER OTC:ALUR
Want to see ALUR full AI Analyst Report?
Top Page
Allurion Technologies
(OTC:ALUR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.77
▼(-3.50% Downside)
Action:ReiteratedDate:04/19/26
The score is held down primarily by weak financial performance (shrinking revenue, large losses, negative equity, and ongoing cash burn). Corporate events add both upside (FDA approval) and significant risk (delisting/OTC transition and dilution-linked financing). Technicals are roughly neutral and valuation is constrained by negative earnings and no dividend.
Positive Factors
Regulatory Approval
PMA approval gives Allurion durable U.S. market access for a non‑invasive gastric balloon, opening an addressable pool of ~80M adults in the indicated BMI range. This structural regulatory clearance materially improves commercialization prospects and legitimizes provider adoption versus off‑label alternatives.
Negative Factors
Weak Balance Sheet
Materially negative equity and a thin asset base constrain strategic flexibility and raise solvency risk. Negative equity reflects cumulative losses and can limit access to non‑dilutive capital, hamper commercial partnerships, and increase the cost of capital needed to fund U.S. rollout after FDA approval.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Approval
PMA approval gives Allurion durable U.S. market access for a non‑invasive gastric balloon, opening an addressable pool of ~80M adults in the indicated BMI range. This structural regulatory clearance materially improves commercialization prospects and legitimizes provider adoption versus off‑label alternatives.
Read all positive factors
Allurion Technologies (ALUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.00M
Dividend YieldN/A
Average Volume (3M)88.72K
Price to Earnings (P/E)―
Beta (1Y)2.67
Revenue Growth-50.49%
EPS Growth39.93%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.61
Shares Outstanding14,994,486
10 Day Avg. Volume45,410
30 Day Avg. Volume88,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.20
Price to Sales (P/S)6.09
P/FCF Ratio-3.21
Enterprise Value/Market Cap2.47
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit3.10
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$5.50Price Target Upside587.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$15.06M
Allurion Technologies Business Overview & Revenue Model
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Bal...
How the Company Makes Money
Allurion generates revenue primarily by selling its Allurion Program to healthcare providers/clinics that offer the program to patients. Under this model, providers purchase Allurion Balloon units and associated program components (which may inclu...
Allurion Technologies Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The call highlighted significant progress in the FDA approval process and successful restructuring efforts that improved financial efficiencies. However, these positives were tempered by a considerable decline in revenue and gross profit. The company's strategic initiatives, such as debt restructuring and R&D advancements, indicate a positive long-term outlook.Positive Updates
FDA Approval Process Milestones
Allurion passed several critical milestones towards FDA approval for the Allurion Smart Capsule, including the completion of the substantive review phase with no observations or Form 483 issued, indicating readiness for the U.S. market.
Negative Updates
Revenue Decline
Revenue for the third quarter of 2025 was $2.7 million, a significant decrease from $5.4 million for the same period in 2024, primarily due to restructuring.
Read all updates
Q3-2025 Updates
Positive
Negative
FDA Approval Process Milestones
Allurion passed several critical milestones towards FDA approval for the Allurion Smart Capsule, including the completion of the substantive review phase with no observations or Form 483 issued, indicating readiness for the U.S. market.
Read all positive updates
Company Guidance
In the third quarter earnings call, Allurion Technologies provided several updates and metrics regarding its financial performance and strategic initiatives. The company reported a revenue of $2.7 million, reflecting a restructuring to focus on accounts promoting metabolically healthy weight loss. Operating expenses decreased by 29% to $10.9 million, narrowing the operating loss to $9.6 million, a 22% improvement from the previous year. Adjusted operating expenses were $8.4 million, and adjusted net operating loss was $6.9 million, both showing significant improvements from the prior year. Allurion also highlighted its progress toward FDA approval for the Allurion Smart Capsule, passing critical milestones such as the pre-approval and BIMO inspections with no observations. Furthermore, the company announced plans to restructure its balance sheet, aiming to be debt-free, and has initiated a transaction to exchange outstanding debt for convertible preferred equity. The strategic pivot to focus on combination therapy with GLP-1s and the development of a drug-eluting balloon as part of its R&D pipeline were emphasized as key components of Allurion's future growth strategy.Allurion Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M |
| Gross Profit | 9.57M | 21.50M | 41.50M | 50.73M | 29.19M |
| EBITDA | -27.70M | -22.17M | -69.03M | -32.28M | -8.01M |
| Net Income | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M |
Balance Sheet | |||||
| Total Assets | 15.77M | 32.81M | 71.71M | 51.37M | 39.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.41M | 15.38M | 38.04M | 7.68M | 25.84M |
| Total Debt | 29.04M | 37.92M | 41.86M | 59.53M | 26.14M |
| Total Liabilities | 92.96M | 110.79M | 142.20M | 83.68M | 73.64M |
| Stockholders Equity | -77.19M | -77.98M | -70.49M | -32.31M | -34.28M |
Cash Flow | |||||
| Free Cash Flow | -28.95M | -42.91M | -65.59M | -48.53M | -15.24M |
| Operating Cash Flow | -28.95M | -42.30M | -63.98M | -46.98M | -14.33M |
| Investing Cash Flow | 0.00 | -611.00K | -1.61M | -1.55M | -912.00K |
| Financing Cash Flow | 18.97M | 20.21M | 95.99M | 30.54M | 28.95M |
Allurion Technologies Technical Analysis
Negative
0.80
Price Trends
0.84
Negative
1.18
Negative
1.71
Negative
Market Momentum
<0.01
Negative
50.37
Neutral
39.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.84, and below the 200-day MA of 1.71, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.37 is Neutral, neither overbought nor oversold. The STOCH value of 39.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.
Allurion Technologies Risk Analysis
Allurion Technologies disclosed 83 risk factors in its most recent earnings report. Allurion Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allurion Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $5.31M | -0.21 | -279.58% | ― | 147.74% | 73.23% | |
44 Neutral | $18.00M | -27.32 | -148.64% | ― | 4.58% | 55.26% | |
44 Neutral | $7.39M | -0.34 | -57.19% | ― | ― | 18.94% | |
43 Neutral | $12.00M | -3.23 | 58.76% | ― | -50.49% | 39.93% | |
43 Neutral | $5.12M | -0.07 | -70.27% | ― | -87.84% | 29.16% | |
42 Neutral | $11.29M | -0.63 | -204.04% | ― | -60.89% | 94.49% |
* Healthcare Sector Average
ALUR
Allurion Technologies
0.80
-1.49
-65.07%
IRIX
Iridex
1.06
0.03
2.91%
SINT
Sintx Technologies
2.69
0.91
51.12%
CODX
Co-Diagnostics
1.56
-9.10
-85.36%
XAIR
Beyond Air
0.54
-4.08
-88.24%
NVNO
enVVeno Medical
11.70
-73.00
-86.19%
Allurion Technologies Corporate Events
Business Operations and StrategyDelistings and Listing Changes
Allurion Faces NYSE Delisting, Shifts Trading to OTC
Negative
Mar 12, 2026
On March 6, 2026, the New York Stock Exchange moved to delist Allurion Technologies’ common stock and warrants after the company fell below the required $15 million average global market capitalization over 30 consecutive trading days, promp...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Allurion Technologies Appeals NYSE Delisting, Plans Compliance Strategy
Negative
Mar 2, 2026
On March 2, 2026, Allurion Technologies announced that it had received a delisting notice from the New York Stock Exchange after failing to meet the exchange’s continued listing standards requiring at least $50 million in stockholders’...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Allurion Technologies Amends Warrants to Bolster Liquidity
Positive
Feb 25, 2026
On February 24, 2026, Allurion Technologies, Inc. entered into an inducement agreement with certain warrant holders to amend existing warrants issued in 2025 by cutting their exercise prices to $1.15 per share. In return, these investors agreed to...
Business Operations and StrategyProduct-Related Announcements
Allurion Wins FDA Approval for Gastric Balloon System
Positive
Feb 23, 2026
On February 23, 2026, Allurion Technologies announced that the U.S. Food and Drug Administration granted PMA approval for its Allurion Gastric Balloon System, featuring the swallowable Allurion Smart Capsule, for adults aged 22 to 65 with obesity ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.